Fosamax works to protect bones 5 years after treatment halted

03/18/2004 | Bloomberg Businessweek · Medscape (free registration)

After 10 years of treatment, Merck's Fosamax continued to work to increase bone density in post-menopausal women, even five years after they had stopped taking the drug, according to a new report. The trial was said to be the longest one conducted for prevention of the bone disease and appeared to offer an alternative for women afraid to take now-controversial hormone-replacement therapy.

View Full Article in:

Bloomberg Businessweek · Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate General Counsel Business Law
Takeda Pharmaceuticals
Cambridge, MA
Quality Engineer
BiOM
Bedford, MA
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA